 |
PDBsum entry 1ej9
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Isomerase/DNA
|
PDB id
|
|
|
|
1ej9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
39:6832-6840
(2000)
|
|
PubMed id:
|
|
|
|
|
| |
|
Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA.
|
|
M.R.Redinbo,
J.J.Champoux,
W.G.Hol.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Human topoisomerase I helps to control the level of DNA supercoiling in cells
and is vital for numerous DNA metabolic events, including replication,
transcription, and recombination. The 2.6 A crystal structure of human
topoisomerase I in noncovalent complex with a DNA duplex containing a cytosine
at the -1 position of the scissile strand rather than the favored thymine is
reported. The hydrogen bond between the O2 position of this -1 base and the
epsilon-amino of the conserved Lys-532 residue, the only base-specific contact
observed previously in the human topoisomerase I-DNA interaction, is maintained
in this complex. Several unique features of this structure, however, have
implications for the DNA-binding and active-site mechanisms of the enzyme.
First, the ends of the DNA duplex were observed to shift by up to 5.4 A
perpendicular to the DNA helical axis relative to structures reported
previously, suggesting a novel degree of plasticity in the interaction between
human topoisomerase I and its DNA substrate. Second, 12 additional residues at
the NH(2) terminus of the protein (Trp-203-Gly-214) could be built in this
structure, and they were found to pack against the putative hinge region
implicated in the clamping of the enzyme around duplex DNA. Third, a water
molecule was observed adjacent to the scissile phosphate and the active-site
residues; the potential specific base character of this solvent molecule in the
active-site mechanism of the enzyme is discussed. Fourth, the scissile phosphate
group was found to be rotated by 75 degrees, bringing Lys-532 into
hydrogen-bonding distance of one of the nonbridging phosphate oxygens. This
orientation of the scissile phosphate group implicates Lys-532 as a fifth
active-site residue, and also mimics the orientation observed for the
3'-phosphotyrosine linkage in the covalent human topoisomerase I-DNA complex
structure. The implications of these structural features for the mechanism of
the enzyme are discussed, including the potential requirement for a rotation of
the scissile phosphate group during DNA strand cleavage and covalent attachment.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Alam,
M.Goyal,
M.S.Iqbal,
S.Bindu,
S.Dey,
C.Pal,
P.Maity,
N.M.Mascarenhas,
N.Ghoshal,
and
U.Bandyopadhyay
(2011).
Cysteine-3 and cysteine-4 are essential for the thioredoxin-like oxidoreductase and antioxidant activities of Plasmodium falciparum macrophage migration inhibitory factor.
|
| |
Free Radic Biol Med,
50,
1659-1668.
|
 |
|
|
|
|
 |
W.Yang
(2011).
Nucleases: diversity of structure, function and mechanism.
|
| |
Q Rev Biophys,
44,
1.
|
 |
|
|
|
|
 |
C.García-Estrada,
C.F.Prada,
C.Fernández-Rubio,
F.Rojo-Vázquez,
and
R.Balaña-Fouce
(2010).
DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery.
|
| |
Proc Biol Sci,
277,
1777-1787.
|
 |
|
|
|
|
 |
C.Tesauro,
P.Fiorani,
I.D'Annessa,
G.Chillemi,
G.Turchi,
and
A.Desideri
(2010).
Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I.
|
| |
Biochem J,
425,
531-539.
|
 |
|
|
|
|
 |
G.Mancini,
I.D'Annessa,
A.Coletta,
N.Sanna,
G.Chillemi,
and
A.Desideri
(2010).
Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex.
|
| |
PLoS One,
5,
e10934.
|
 |
|
|
|
|
 |
K.Perry,
Y.Hwang,
F.D.Bushman,
and
G.D.Van Duyne
(2010).
Insights from the structure of a smallpox virus topoisomerase-DNA transition state mimic.
|
| |
Structure,
18,
127-137.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Punchihewa,
M.Carver,
and
D.Yang
(2009).
DNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin.
|
| |
Protein Sci,
18,
1326-1331.
|
 |
|
|
|
|
 |
J.Malina,
O.Vrana,
and
V.Brabec
(2009).
Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes.
|
| |
Nucleic Acids Res,
37,
5432-5442.
|
 |
|
|
|
|
 |
L.Shuai,
S.Wang,
L.Zhang,
B.Fu,
and
X.Zhou
(2009).
Cationic porphyrins and analogues as new DNA topoisomerase I and II inhibitors.
|
| |
Chem Biodivers,
6,
827-837.
|
 |
|
|
|
|
 |
O.Szklarczyk,
K.Staroń,
and
M.Cieplak
(2009).
Native state dynamics and mechanical properties of human topoisomerase I within a structure-based coarse-grained model.
|
| |
Proteins,
77,
420-431.
|
 |
|
|
|
|
 |
Z.Liu,
R.Meng,
Y.Zu,
Q.Li,
and
L.Yao
(2009).
Imaging and studying human topoisomerase I on mica surfaces in air and in liquid by atomic force microscopy.
|
| |
Scanning,
31,
160-166.
|
 |
|
|
|
|
 |
A.J.Schoeffler,
and
J.M.Berger
(2008).
DNA topoisomerases: harnessing and constraining energy to govern chromosome topology.
|
| |
Q Rev Biophys,
41,
41.
|
 |
|
|
|
|
 |
C.A.Prata,
X.X.Zhang,
D.Luo,
T.J.McIntosh,
P.Barthelemy,
and
M.W.Grinstaff
(2008).
Lipophilic peptides for gene delivery.
|
| |
Bioconjug Chem,
19,
418-420.
|
 |
|
|
|
|
 |
F.Animati,
M.Berettoni,
M.Bigioni,
M.Binaschi,
P.Felicetti,
L.Gontrani,
O.Incani,
A.Madami,
E.Monteagudo,
L.Olivieri,
S.Resta,
C.Rossi,
and
A.Cipollone
(2008).
Synthesis, biological evaluation, and molecular modeling studies of rebeccamycin analogues modified in the carbohydrate moiety.
|
| |
ChemMedChem,
3,
266-279.
|
 |
|
|
|
|
 |
G.Chillemi,
I.D'Annessa,
P.Fiorani,
C.Losasso,
P.Benedetti,
and
A.Desideri
(2008).
Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations.
|
| |
Nucleic Acids Res,
36,
5645-5651.
|
 |
|
|
|
|
 |
K.Palle,
L.Pattarello,
M.van der Merwe,
C.Losasso,
P.Benedetti,
and
M.A.Bjornsti
(2008).
Disulfide Cross-links Reveal Conserved Features of DNA Topoisomerase I Architecture and a Role for the N Terminus in Clamp Closure.
|
| |
J Biol Chem,
283,
27767-27775.
|
 |
|
|
|
|
 |
D.Montaudon,
K.Palle,
L.P.Rivory,
J.Robert,
C.Douat-Casassus,
S.Quideau,
M.A.Bjornsti,
and
P.Pourquier
(2007).
Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505.
|
| |
J Biol Chem,
282,
14403-14412.
|
 |
|
|
|
|
 |
G.Chillemi,
A.Bruselles,
P.Fiorani,
S.Bueno,
and
A.Desideri
(2007).
The open state of human topoisomerase I as probed by molecular dynamics simulation.
|
| |
Nucleic Acids Res,
35,
3032-3038.
|
 |
|
|
|
|
 |
I.Choi,
C.Kim,
and
S.Choi
(2007).
Binding mode analysis of topoisomerase inhibitors, 6-arylamino-7-chloro-quinazoline-5,8-diones, within the cleavable complex of human topoisomerase I and DNA.
|
| |
Arch Pharm Res,
30,
1526-1535.
|
 |
|
|
|
|
 |
R.F.Frøhlich,
C.Veigaard,
F.F.Andersen,
A.K.McClendon,
A.C.Gentry,
A.H.Andersen,
N.Osheroff,
T.Stevnsner,
and
B.R.Knudsen
(2007).
Tryptophane-205 of human topoisomerase I is essential for camptothecin inhibition of negative but not positive supercoil removal.
|
| |
Nucleic Acids Res,
35,
6170-6180.
|
 |
|
|
|
|
 |
A.Patel,
S.Shuman,
and
A.Mondragón
(2006).
Crystal structure of a bacterial type IB DNA topoisomerase reveals a preassembled active site in the absence of DNA.
|
| |
J Biol Chem,
281,
6030-6037.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.T.Stivers,
and
R.Nagarajan
(2006).
Probing enzyme phosphoester interactions by combining mutagenesis and chemical modification of phosphate ester oxygens.
|
| |
Chem Rev,
106,
3443-3467.
|
 |
|
|
|
|
 |
K.Perry,
Y.Hwang,
F.D.Bushman,
and
G.D.Van Duyne
(2006).
Structural basis for specificity in the poxvirus topoisomerase.
|
| |
Mol Cell,
23,
343-354.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
B.B.Das,
N.Sen,
S.B.Dasgupta,
A.Ganguly,
and
H.K.Majumder
(2005).
N-terminal region of the large subunit of Leishmania donovani bisubunit topoisomerase I is involved in DNA relaxation and interaction with the smaller subunit.
|
| |
J Biol Chem,
280,
16335-16344.
|
 |
|
|
|
|
 |
J.B.Leppard,
and
J.J.Champoux
(2005).
Human DNA topoisomerase I: relaxation, roles, and damage control.
|
| |
Chromosoma,
114,
75-85.
|
 |
|
|
|
|
 |
L.Sari,
and
I.Andricioaei
(2005).
Rotation of DNA around intact strand in human topoisomerase I implies distinct mechanisms for positive and negative supercoil relaxation.
|
| |
Nucleic Acids Res,
33,
6621-6634.
|
 |
|
|
|
|
 |
L.Tian,
C.D.Claeboe,
S.M.Hecht,
and
S.Shuman
(2005).
Mechanistic plasticity of DNA topoisomerase IB: phosphate electrostatics dictate the need for a catalytic arginine.
|
| |
Structure,
13,
513-520.
|
 |
|
|
|
|
 |
P.L.Carl,
B.R.Temple,
and
P.L.Cohen
(2005).
Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity.
|
| |
Arthritis Res Ther,
7,
R1360-R1374.
|
 |
|
|
|
|
 |
G.Chillemi,
M.Redinbo,
A.Bruselles,
and
A.Desideri
(2004).
Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics.
|
| |
Biophys J,
87,
4087-4097.
|
 |
|
|
|
|
 |
H.Interthal,
P.M.Quigley,
W.G.Hol,
and
J.J.Champoux
(2004).
The role of lysine 532 in the catalytic mechanism of human topoisomerase I.
|
| |
J Biol Chem,
279,
2984-2992.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.J.Vermeersch,
S.Christmann-Franck,
L.V.Karabashyan,
S.Fermandjian,
G.Mirambeau,
and
P.A.Der Garabedian
(2004).
Pyridoxal 5'-phosphate inactivates DNA topoisomerase IB by modifying the lysine general acid.
|
| |
Nucleic Acids Res,
32,
5649-5657.
|
 |
|
|
|
|
 |
K.D.Corbett,
and
J.M.Berger
(2004).
Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases.
|
| |
Annu Rev Biophys Biomol Struct,
33,
95.
|
 |
|
|
|
|
 |
L.Tian,
C.D.Claeboe,
S.M.Hecht,
and
S.Shuman
(2004).
Remote phosphate contacts trigger assembly of the active site of DNA topoisomerase IB.
|
| |
Structure,
12,
31-40.
|
 |
|
|
|
|
 |
S.Antony,
J.A.Theruvathu,
P.J.Brooks,
D.T.Lesher,
M.Redinbo,
and
Y.Pommier
(2004).
Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2'-deoxyguanosine.
|
| |
Nucleic Acids Res,
32,
5685-5692.
|
 |
|
|
|
|
 |
S.Antony,
P.B.Arimondo,
J.S.Sun,
and
Y.Pommier
(2004).
Position- and orientation-specific enhancement of topoisomerase I cleavage complexes by triplex DNA structures.
|
| |
Nucleic Acids Res,
32,
5163-5173.
|
 |
|
|
|
|
 |
C.Bailly
(2003).
Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs.
|
| |
Crit Rev Oncol Hematol,
45,
91.
|
 |
|
|
|
|
 |
G.Chillemi,
P.Fiorani,
P.Benedetti,
and
A.Desideri
(2003).
Protein concerted motions in the DNA-human topoisomerase I complex.
|
| |
Nucleic Acids Res,
31,
1525-1535.
|
 |
|
|
|
|
 |
J.E.Chrencik,
A.B.Burgin,
Y.Pommier,
L.Stewart,
and
M.R.Redinbo
(2003).
Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex.
|
| |
J Biol Chem,
278,
12461-12466.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.O.Christensen,
H.U.Barthelmes,
F.Boege,
and
C.Mielke
(2003).
Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro.
|
| |
Nucleic Acids Res,
31,
7255-7263.
|
 |
|
|
|
|
 |
P.B.Arimondo,
S.Angenault,
L.Halby,
A.Boutorine,
F.Schmidt,
C.Monneret,
T.Garestier,
J.S.Sun,
C.Bailly,
and
C.Hélène
(2003).
Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin-oligonucleotide conjugates.
|
| |
Nucleic Acids Res,
31,
4031-4040.
|
 |
|
|
|
|
 |
Y.Chen,
and
P.A.Rice
(2003).
The role of the conserved Trp330 in Flp-mediated recombination. Functional and structural analysis.
|
| |
J Biol Chem,
278,
24800-24807.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Chen,
and
P.A.Rice
(2003).
New insight into site-specific recombination from Flp recombinase-DNA structures.
|
| |
Annu Rev Biophys Biomol Struct,
32,
135-159.
|
 |
|
|
|
|
 |
B.O.Krogh,
and
S.Shuman
(2002).
Proton relay mechanism of general acid catalysis by DNA topoisomerase IB.
|
| |
J Biol Chem,
277,
5711-5714.
|
 |
|
|
|
|
 |
C.Marchand,
P.Pourquier,
G.S.Laco,
N.Jing,
and
Y.Pommier
(2002).
Interaction of human nuclear topoisomerase I with guanosine quartet-forming and guanosine-rich single-stranded DNA and RNA oligonucleotides.
|
| |
J Biol Chem,
277,
8906-8911.
|
 |
|
|
|
|
 |
D.T.Lesher,
Y.Pommier,
L.Stewart,
and
M.R.Redinbo
(2002).
8-Oxoguanine rearranges the active site of human topoisomerase I.
|
| |
Proc Natl Acad Sci U S A,
99,
12102-12107.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.B.Arimondo,
A.Boutorine,
B.Baldeyrou,
C.Bailly,
M.Kuwahara,
S.M.Hecht,
J.S.Sun,
T.Garestier,
and
C.Hélène
(2002).
Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage by topoisomerase I.
|
| |
J Biol Chem,
277,
3132-3140.
|
 |
|
|
|
|
 |
Y.Pommier,
G.Kohlhagen,
G.S.Laco,
H.Kroth,
J.M.Sayer,
and
D.M.Jerina
(2002).
Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site.
|
| |
J Biol Chem,
277,
13666-13672.
|
 |
|
|
|
|
 |
G.Chillemi,
T.Castrignanò,
and
A.Desideri
(2001).
Structure and hydration of the DNA-human topoisomerase I covalent complex.
|
| |
Biophys J,
81,
490-500.
|
 |
|
|
|
|
 |
J.J.Champoux
(2001).
DNA topoisomerases: structure, function, and mechanism.
|
| |
Annu Rev Biochem,
70,
369-413.
|
 |
|
|
|
|
 |
Y.Chen,
U.Narendra,
L.E.Iype,
M.M.Cox,
and
P.A.Rice
(2000).
Crystal structure of a Flp recombinase-Holliday junction complex: assembly of an active oligomer by helix swapping.
|
| |
Mol Cell,
6,
885-897.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |